Health Care Equipment & Services

Guardant Health insider activity shows CEO Chris Freeman buying 24k shares at $32.86 while selling at $118.67—signaling confidence amid a broader sell‑wave and robust biotech outlook.

BX Mozart’s sizable Medline stake signals PE confidence in its supply‑chain strengths and IPO‑unlocking liquidity, hinting at mid‑term upside amid market volatility.

Hellman & Friedman’s May 2026 Medline trade shifts to Class A shares, signaling a strategic realignment and confidence in the supplier’s resilient cash‑flow model.

Insider buys at Align Technology signal confidence in its digital orthodontics strategy and near‑term outlook, with executives adding RSUs for future upside.

Henry Schein’s modest insider sale shows routine portfolio‑rebalance, not distress—backed by solid fundamentals, tech‑driven supply‑chain gains, and value‑based care momentum.

Option Care Health’s insider buying signals long‑term confidence, revealing a steady accumulation of shares amid a solid valuation and growing home‑care market potential.

Discover how McKesson’s insider trades reveal its tech‑driven strategy for safer pharmacy distribution and smarter drug supply chain analytics.

JW Asset Management’s recent ELHI share sale shows a cautious rebalancing strategy amid rising prices, offering long‑term investors a clear view of risk‑management and growth prospects.

Acme United’s insider moves: COO Brian Olschan’s mixed buy‑sell trades reveal confidence and short‑term liquidity needs, yet little impact on market value.

Guardant Health insider sales on May 20, 2026 are routine portfolio moves, not distress signals—yet investors should watch for accelerating selling that could hint at changing confidence.